# The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

> **NCT05042973** · PHASE2 · COMPLETED · sponsor: **Jacob Moller** · enrollment: 165 (actual)

## Conditions studied

- Obesity
- Heart Failure

## Interventions

- **DRUG:** Empagliflozin 10 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05042973
- **Lead sponsor:** Jacob Moller
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-02
- **Primary completion:** 2025-01-16
- **Final completion:** 2025-01-23
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2025-01-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05042973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05042973, "The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05042973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*